| |
Wednesday, January 15, 2025 | 11am ET / 8am PT Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now. 
|
|
Today’s Big NewsJan 6, 2025 |
|
The U.S. Department of Veterans Affairs (VA) is at the forefront of healthcare innovation, developing cutting-edge technologies to improve the lives of veterans . Now, your business can leverage these advancements. Download today to learn more! 
|
|
| By Fraiser Kansteiner From condemning the Jan. 6 Capitol riots to helping fund the president-elect’s impending inauguration, recent years have seen biopharma leaders learn to embrace a "live and let live" mentality when it comes to Donald Trump. |
|
|
|
By Conor Hale The FDA has published a set of long-awaited recommendations to the industry to help ensure pulse oximeters work correctly across all skin tones. |
By Gabrielle Masson Overall, biopharma layoffs rose ever so slightly in 2024 compared to the year before, though the number of layoff rounds across Big Pharma companies skyrocketed by 281%. |
By Angus Liu In a draft guidance document, the FDA specified criteria to determine if a confirmatory trial is “underway” prior to an accelerated approval. |
|
As the market for complex biologics continues to grow, effective capacity planning becomes more challenging. The entry of the 5,000L single-use bioreactor (SUB) is providing an important bridge between small-scale and large-scale production, offering more flexibility than ever before to respond to fluctuations in demand quickly and efficiently. Access this report to learn more. 
|
|
By Nick Paul Taylor I-Mab has begun the new year with a pipeline pivot, pausing work on an asset Sanofi bought into last year to focus on its play for the congested CLDN18.2 space. |
By Nick Paul Taylor Amylyx Pharmaceuticals has named Dan Monahan as chief commercial officer, positioning an exec who led the U.S. commercialization of Otsuka's Rexulti to oversee the planned launch of a GLP-1 receptor antagonist. |
By Kevin Dunleavy With the potential passage of the BIOSECURE Act looming and WuXi Biologics seeing its share price and profits decline, the Chinese biopharma contract manufacturing giant is responding with a large divestiture. |
By Darren Incorvaia British tech firm Basecamp Research is making a big push forward to further its mission of developing programmable genetic medicines. The company has hired gene therapy vet John Finn, Ph.D., to be its new chief scientific officer, working out of a new office and lab space in Cambridge, Massachusetts. |
By Zoey Becker The company had initially hoped to launch its first product, T-cell lymphoma treatment Lymphir, within five months of its August FDA nod. |
By Gabrielle Masson The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Andrea Park As the 2025 Hollywood awards season kicked off with the Golden Globes on Sunday night, so too did another round of jokes, speculation and sponsorships linking the industry to the use of GLP-1 medications for weight loss. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we bring you a special conversation from earlier this month at our New York City gala, where we celebrated this year’s Fierce 50 honorees. |
|
|---|
|
|
|
With unique perspectives from key opinion leaders, this whitepaper examines the challenges associated with process development and manufacturing of cell and gene therapies. Download now to take your cell and gene therapy techniques to new heights. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
